Exane Derivatives Purchases Shares of 62,153 Sema4 Holdings Corp. (NASDAQ:SMFR)

Exane Derivatives purchased a new stake in shares of Sema4 Holdings Corp. (NASDAQ:SMFRGet Rating) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 62,153 shares of the company’s stock, valued at approximately $78,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of SMFR. Bank of America Corp DE lifted its position in shares of Sema4 by 211.3% during the first quarter. Bank of America Corp DE now owns 34,721 shares of the company’s stock worth $106,000 after purchasing an additional 23,568 shares in the last quarter. Gabelli Funds LLC lifted its position in shares of Sema4 by 80.0% during the first quarter. Gabelli Funds LLC now owns 22,500 shares of the company’s stock worth $69,000 after purchasing an additional 10,000 shares in the last quarter. Ensign Peak Advisors Inc lifted its position in shares of Sema4 by 144.7% during the first quarter. Ensign Peak Advisors Inc now owns 57,760 shares of the company’s stock worth $177,000 after purchasing an additional 34,160 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Sema4 by 61.7% during the first quarter. Goldman Sachs Group Inc. now owns 150,981 shares of the company’s stock worth $463,000 after purchasing an additional 57,612 shares in the last quarter. Finally, State Street Corp lifted its position in shares of Sema4 by 83.8% during the first quarter. State Street Corp now owns 1,137,530 shares of the company’s stock worth $3,492,000 after purchasing an additional 518,620 shares in the last quarter.

Sema4 Stock Down 7.6 %

SMFR stock opened at $0.92 on Thursday. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.97 and a quick ratio of 1.76. Sema4 Holdings Corp. has a 1-year low of $0.91 and a 1-year high of $9.18. The firm has a fifty day moving average price of $1.42 and a two-hundred day moving average price of $1.93. The firm has a market cap of $348.58 million, a price-to-earnings ratio of -1.59 and a beta of 2.08.

Insider Buying and Selling at Sema4

In other Sema4 news, CFO Isaac Ro sold 20,245 shares of the business’s stock in a transaction on Tuesday, August 9th. The shares were sold at an average price of $1.99, for a total transaction of $40,287.55. Following the completion of the sale, the chief financial officer now owns 244,041 shares in the company, valued at $485,641.59. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders sold a total of 32,378 shares of company stock worth $57,876 over the last 90 days.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. The Goldman Sachs Group assumed coverage on shares of Sema4 in a research report on Thursday, June 2nd. They set a “buy” rating and a $3.50 target price on the stock. Jefferies Financial Group lowered shares of Sema4 from a “buy” rating to a “hold” rating and dropped their price target for the stock from $4.00 to $2.00 in a research note on Tuesday, August 16th. Finally, BTIG Research dropped their price target on shares of Sema4 from $5.00 to $3.00 and set a “buy” rating for the company in a research note on Thursday, August 18th. One investment analyst has rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $3.70.

Sema4 Company Profile

(Get Rating)

Sema4 Holdings Corp., doing business as Sema4, operates as a health information company that enhances diagnosis, treatment, and prevention of disease through data. The company provides Centrellis, an AI-driven health intelligence platform that delivers comprehensive insights to biopharma to accelerate the drug discovery, development, and commercialization life-cycle, as well as analytics for actionable insights, pre-clinical and clinical trial support, and advanced sequencing services.

Featured Articles

Institutional Ownership by Quarter for Sema4 (NASDAQ:SMFR)

Receive News & Ratings for Sema4 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sema4 and related companies with MarketBeat.com's FREE daily email newsletter.